TY - JOUR AU - Volkov, O.O. AU - Klygunenko, O.M. AU - Lutsenko, V.V. PY - 2019/05/28 Y2 - 2024/03/28 TI - Selection of intravenous fluids for perioperative volemic support JF - EMERGENCY MEDICINE JA - ЕМ VL - IS - 3.98 SE - Scientific Review DO - 10.22141/2224-0586.3.98.2019.165471 UR - https://emergency.zaslavsky.com.ua/index.php/journal/article/view/1115 SP - 9-13 AB - The use of hydroxyethyl starch (HES) has become controversial in the past two decades after increasing the number of studies on critical ill patients, showing that its use was associated with an increased incidence of acute kidney injury (AKI) or even mortality. Some of these studies had significant problems regarding the methodology. For example, in some studies HES was administered before randomization, the assessment of hypovolemia was insufficient, there was a long-term administration of HES, or the volume received exceeded the maximum dose. Infusion agents should be considered as drugs for avoi­ding unnecessary preoperative fasting, infusion-related adverse effects, and it allows creating basic targeted volemic therapy by conducting more in-depth studies. The choice of the fluid type to prevent hyperchloremic metabolic acidosis in the perioperative period and the unfavorable association of HES with hemostasis and renal dysfunction does not allow scientific debate to stop with the designation of a specific scheme of perioperative infusion therapy. This review shows the data of approaches in fluid resuscitation and the effect on the results in the perioperative settings. The choice of the fluid type is a key position due to the high frequency of hyperchloremia, hyperkalemia and metabolic acidosis associated with the use of large volumes of saline, and reports the correlation of HES with blood clotting disorders and renal complications. None of the studies were able to detect the difference in acute kidney damage between the hydroxyethyl starch of the current generation and the crystalloids in surgical patients. The quality and level of evidence in the available lite­rature is too low to conclude whether HES has a favorable or unfavorable profile in the treatment of acute perioperative hypovolemia. When hydroxyethyl starch is used, the recommended dose should not be exceeded, and its use should be limited to non-septic patients without history of renal failure. ER -